Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

W A Stack, S D Mann, A J Roy, P Heath, M Sopwith, J Freeman, G Holmes, R Long, A Forbes, M A Kamm

Research output: Contribution to journalArticlepeer-review

416 Citations (Scopus)


Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease.
Original languageEnglish
Pages (from-to)521-524
Number of pages4
JournalThe Lancet
Issue number9051
Publication statusPublished - 22 Feb 1997


  • Adolescent
  • Adult
  • Aged
  • Antibodies
  • C-Reactive Protein
  • Crohn Disease
  • Double-Blind Method
  • Glycoproteins
  • Humans
  • Middle Aged
  • Placebos
  • Remission Induction
  • Tumor Necrosis Factor-alpha

Cite this